Time-Adjusted Internal Target Volume: A Novel Approach Focusing on Heterogeneity of Tumor Motion Based on 4-Dimensional Computed Tomography Imaging for Radiation Therapy Planning of Lung Cancer-Reference-Cited by-同舟云学术

Time-Adjusted Internal Target Volume: A Novel Approach Focusing on Heterogeneity of Tumor Motion Based on 4-Dimensional Computed Tomography Imaging for Radiation Therapy Planning of Lung Cancer

Published:2014-08 Issue:5 Volume:89 Page:1129-1137
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Nishibuchi Ikuno,Kimura Tomoki,Nakashima Takeo,Ochi Yusuke,Takahashi Ippei,Doi Yoshiko,Kenjo Masahiro,Kaneyasu Yuko,Ozawa Syuichi,Murakami Yuji,Wadasaki Koichi,Nagata Yasushi

Publisher

Elsevier BV

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,Radiation

Reference25 articles.

1. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame;Nagata;Int J Radiat Oncol Biol Phys,2005

2. Uncertainties in CT-based radiation therapy treatment planning associated with patient breathing;Balter;Int J Radiat Oncol Biol Phys,1996

3. Impact of respiratory movement on the computed tomographic images of small lung tumors in three-dimensional (3D) radiotherapy;Shimizu;Int J Radiat Oncol Biol Phys,2000

4. Artifacts in computed tomography scanning of moving objects;Chen;Semin Radiat Oncol,2004

5. The impact of tumor motion upon CT image integrity and target delineation;Gagne;Med Phys,2004

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dosimetric comparison of free-breathing versus respiratory motion-managed radiotherapy via four-dimensional computed tomography-based volumetric-modulated arctherapy for lung cancer;Cancer/Radiothérapie;2023-12

A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors

;Lung Cancer: Targets and Therapy;2019-09